We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Moderna, a frontrunner in the race to develop a COVID-19 vaccine, announced Thursday that its phase 3 study for the candidate could start by early summer. Read More
A failed study of nearly 1,400 COVID-19 patients taking hydroxychloroquine is the latest to cast doubt on the drug’s benefit as a coronavirus treatment. Read More
Incyte and Novartis are planning a second phase 3 clinical trial in the U.S. of their JAK inhibitor Jakafi (ruxolitinib) as a COVID-19 treatment. Read More
The FDA’s Center for Biologics Evaluation and Research (CBER) Director Peter Marks said Wednesday that he hopes the center can help expedite vaccine development to lead to a COVID-19 vaccine in nine months. Read More
Pfizer and BioNTech have started a U.S. trial of COVID-19 vaccine candidates at the NYU Grossman School of Medicine and the University of Maryland School of Medicine. Read More
More than a dozen countries — with the notable exception of the United States — have pledged to contribute approximately $8 billion to develop potential COVID-19 vaccines and treatments. Read More